Reported about 15 hours ago
Pfizer is set to acquire Metsera, an anti-obesity drug manufacturer, for $4.9 billion, paying $47.50 per share with potential increases based on performance milestones. This acquisition comes after Pfizer's own obesity treatment faced challenges earlier this year. The news has led to a surge in Metsera's stock and a positive response in Pfizer's share price.
Source: YAHOO